Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hyperlipoproteinemia Type II 1Endometrial Neoplasms 1

Interventions

Gemcitabine 6Irinotecan 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Specimen Handling 3Leucovorin 3Fluorouracil 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3palbociclib 2olaparib 2cobimetinib 2Radiosurgery 2Positron-Emission Tomography 2Oncolytic Virotherapy 2Nivolumab 2Ketamine 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Disulfides 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trastuzumab biosimilar HLX02 1toripalimab 1sonidegib 1semaglutide 1pimonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pancreatic Neoplasms × Ezetimibe × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡